Transarterial Infusion of Cisplatin and Doxorubicin in Bladder Cancer: Original Article

Mokarim, Abul; Uetani, Masataka; Sakamoto, Ichiro; Hayashi, Nobuyuki; Nomata, Koichiro; Oda, Hiroshi

doi:10.3109/02841869709109227

Cited by 9 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In 1987, combined chemotherapy and radiation therapy (with systemic delivery of cisplatin) proved a viable treatment alternative to radical cystectomy in patients with invasive bladder carcinoma ( 84 ). To reduce systemic toxicities and improve response rate, intraarterial chemoinfusion was proposed ( 85 ). In a 1997 phase II trial, Mokarim et al ( 86 ) reported a 74% complete response rate and a 76.6% actuarial 5-year survival.…”

Section: Intraarterial Chemoinfusion Backgroundmentioning

confidence: 98%

Transcatheter Intraarterial Therapies: Rationale and Overview

Lewandowski¹,

Geschwind²,

Liapi³

et al. 2011

Radiology

216

169

View full text Add to dashboard Cite

Transcatheter intraarterial therapies have proved valuable in the battle against primary and secondary hepatic malignancies. The unique aspects of all such therapies are their reduced toxicity profiles and highly effective tumor responses. These unique characteristics coupled with their minimally invasive nature provide an attractive therapeutic option in patients who may have previously had few alternatives. The concept of all catheter-based intraarterial therapies is to selectively deliver anticancer treatment to tumor(s). These therapies, which include transarterial embolization, intraarterial chemoinfusion, transarterial chemoembolization with or without drug-eluting beads, and radioembolization with use of yttrium 90, inflict lethal insult to tumors while preserving normal hepatic parenchyma. This is possible because hepatic neoplasms preferentially derive their blood supply from an arterial source while the majority of noncancerous liver is supplied by the portal vein. As part of the interventional oncology review series, in this article we describe the rationale behind each of these transcatheter therapies and provide a review of the existing medical literature.

show abstract

Section: Intraarterial Chemoinfusion Backgroundmentioning

confidence: 98%

Transcatheter Intraarterial Therapies: Rationale and Overview

Lewandowski¹,

Geschwind²,

Liapi³

et al. 2011

Radiology

216

169

View full text Add to dashboard Cite

show abstract

“…Mokarim et al reported a bladder preservation rate following TAI of 70% -71%. It is possible that TAI + radiation is a more effective treatment option for MIBT [6,7].…”

Section: Discussionmentioning

confidence: 99%

The Role of Serum Cytokeratin 19 Fragment in Transarterial Infusion against Invasive Bladder Cancer

Takahashi

Kimata²,

Nomura³

et al. 2013

OJU

View full text Add to dashboard Cite

Background: We used transcatheter arterial infusion chemotherapy (TAI) for patients with T1G3 and greater than T2 bladder cancer, which was diagnosed after extensive and deep transurethral resection of bladder tumor (TUR-BT), and we investigated the utility of serum cytokeratin 19 fragment (CYFRA) as a predictive factor of the response to therapy. Material and Methods: From November 2001 to November 2010, 56 patients (46 males and 10 females) with pathologically confirmed T1 G3 or greater than T2 bladder cancer after TUR-BT underwent two courses of TAI of cisplatin, methotrexate and doxorubicin as neoadjuvant setting. Then, patients underwent evaluation TUR-BT. Thereafter, the bladder was preserved in patients with superficial or undetectable tumors on TUR-BT. Advanced cases and residual bladder tumor cases were treated with total cystectomy or systemic chemotherapy. CYFRA levels were measured before and after performing TAI. Results: With this therapy, the 5-year survival rate was 85.7% in pT1G3, 82.3% in pT2, and 66.6% in greater than pT3 cases. Bladder preservation with no recurrence was observed in 58.7% of the patients. Grade III adverse events included leucopenia (6/56 patients: 10.7%). Serum CYFRA levels significantly decreased with treatment (in 4/6 patients with elevated CYFRA levels). Conclusion: These results suggest that although total cystictomy is usually indicated for T1G3 bladder cancers, bladder preservation and control of micrometastases can be achieved by performing TAI after extensive and deep TUR-BT. Our results also suggest the utility of monitoring serum CYFRA to assess the response to therapy.

show abstract

“…Στο πρωτόκολλό µας τα χηµειοθεραπευτικά που χρησιµοποιήθηκαν ήταν η epirubicin για ΠΕΧ/Θ και η 5-FU για συστηµατική ΧΘ. Λίγες τεκµηριωµένες µελέτες θεραπευτικής αντιµετώπισης καρκίνου ουροδόχου κύστης είναι διαθέσιµες µε τον παραπάνω συνδυασµό 102 .…”

Section: συζητησηunclassified

Η Περιοχική Ενδαρτηριακή Χημειοθεραπεία Του Προχωρημένου Καρκίνου Της Ουροδόχου Κύστης

Παναγιωτίδης¹

View full text Add to dashboard Cite

ΠΕΡΙΕΧΟΜΕΝΑ Πρόλογος…………………………………………………………………… Eισαγωγή………………………………………………………………… Α΄ ΓΕΝΙΚΟ ΜΕΡΟΣ Κεφάλαιο Ι Ανατοµία της ουροδόχου κύστης Κεφάλαιο ΙΙ Μορφολογία της ουροδόχου κύστης Κεφάλαιο ΙΙΙ Βιολογική προσέγγιση του καρκίνου της ουροδόχου κύστης Θεωρίες αναφορικά µε τα πιθανά αίτια εµφάνισης του καρκίνου της ουροδόχου κύστης Προγνωστικοί παράγοντες στον καρκίνο της ουροδόχου κύστης Επιδηµιολογία του καρκίνου της ουροδόχου κύστης Κεφάλαιο IV Θεραπευτική αντιµετώπιση του καρκίνου της ουροδόχου κύστης Α. Μη διηθητικού α. ∆ιουρηθρική εκτοµή β. Ενδοκυστικές εγχύσεις γ. Φωτοθεραπεία µε αιµατοπορφυρίνη δ. Laser ε. Θεραπεία µε υδροστατική πίεση στ. Απόξεση βλεννογόνου ζ. Κυστεκτοµή Β. ∆ιηθητικού α. ∆ιουρηθρική εκτοµή του διηθητικού καρκίνου β. Μερική ή ριζική κυστεκτοµή γ. Ακτινοθεραπεία δ. Συστηµατική χηµειοθεραπεία ε. Συστηµατική ανοσοθεραπεία στ. Περιοχική χηµειοθεραπεία Β΄ ΕΙ∆ΙΚΟ ΜΕΡΟΣ Υλικό και µέθοδος µελέτης Κεφάλαιο V Αποτελέσµατα Κεφάλαιο VI Στατιστική ανάλυση των αποτελεσµάτων

show abstract

Transarterial Infusion of Cisplatin and Doxorubicin in Bladder Cancer: Original Article

Cited by 9 publications

References 21 publications

Transcatheter Intraarterial Therapies: Rationale and Overview

Transcatheter Intraarterial Therapies: Rationale and Overview

The Role of Serum Cytokeratin 19 Fragment in Transarterial Infusion against Invasive Bladder Cancer

Η Περιοχική Ενδαρτηριακή Χημειοθεραπεία Του Προχωρημένου Καρκίνου Της Ουροδόχου Κύστης

Contact Info

Product

Resources

About